60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

• Market Cap: $5.79M
• Dividend Yield: N/A
• Average Volume (3M): 120.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.35
• Revenue Growth: 120.67%
• EPS Growth: -456.33%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -1.16
• Shares Outstanding: 4,104,469
• 10 Day Avg. Volume: 85,714
• 30 Day Avg. Volume: 120,462
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.93
• Enterprise Value/Revenue: 11.62
• Enterprise Value/Gross Profit: 40.22
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: $7.00
• Price Target Upside: 379.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: $1.00 ▼(-31.51% Downside)

SXTP's overall stock score is weighed down by poor financial performance and weak technical indicators. While the recent capital injection is a positive development, significant challenges in profitability and valuation remain.

Positive Factors

Drug Approval

Arakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, which is a rare seasonal disease.

Financial Performance

Product revenues showed a significant year-over-year increase, despite being supply-constrained.

Market Opportunity

The company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.

Sales Growth

Arakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.

Negative Factors

Earnings

Q1 earnings per share were below estimates due to higher than forecast SG&A expenses.

Equity

The company raised a net $1.9 million of equity, extending its financial runway.

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

How the Company Makes Money

60 Degrees Pharmaceuticals, Inc. generates revenue through the development and sale of pharmaceutical products designed to treat and prevent tropical diseases. The company earns income from product sales, licensing agreements, and research and development collaborations. Key revenue streams include government contracts, partnerships with non-governmental organizations, and sales to international markets where tropical diseases are prevalent. Additionally, the company may receive funding and grants from global health initiatives and foundations that support the fight against infectious diseases.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary

SXTP is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flow. Despite improvements in equity and reduced debt, profitability and cash generation are major concerns.

Income Statement

The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.

Balance Sheet

The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.

Cash Flow

The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	960.89K	681.35K	253.57K	223.21K	1.16M	2.55M
Gross Profit	277.54K	222.81K	-220.98K	-209.16K	309.60K	1.48M
EBITDA	-7.64M	-7.88M	-1.43M	-2.11M	-1.01M	-341.17K
Net Income	-7.80M	-7.95M	-3.77M	-6.18M	-4.25M	-3.03M
Balance Sheet
Total Assets	4.18M	5.76M	7.78M	1.30M	1.39M	2.61M
Cash, Cash Equivalents and Short-Term Investments	1.97M	3.39M	2.14M	264.87K	115.40K	191.70K
Total Debt	154.25K	155.89K	172.67K	22.42M	18.80M	19.14M
Total Liabilities	1.84M	1.80M	2.99M	25.45M	19.55M	20.68M
Stockholders Equity	2.43M	4.04M	4.87M	-23.58M	-17.58M	-17.50M
Cash Flow
Free Cash Flow	-3.36M	-5.83M	-4.66M	-1.07M	-684.50K	-238.28K
Operating Cash Flow	-3.32M	-5.65M	-4.54M	-1.01M	-649.11K	-167.30K
Investing Cash Flow	-97.91K	-1.89M	-115.89K	-60.13K	-35.39K	-70.98K
Financing Cash Flow	6.85M	7.05M	6.47M	1.22M	611.23K	277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 1.46 is above the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.65, and below the 200-day MA of 3.07, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 53.98 is Neutral, neither overbought nor oversold. The STOCH value of 84.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.90B	-0.33	-41.69%	2.23%	23.45%	-1.99%
SXTP	39 Underperform	$5.79M	―	-285.78%	―	120.67%	-456.33%
ETHZ	―	$439.07M	―	-371.02%	―	―	―
ADIL	32 Underperform	$8.29M	―	-171.27%	―	―	75.96%
SILO	―	$6.01M	―	-90.03%	―	―	―
ALZN	―	$7.01M	―	-657.17%	―	―	―
DRMA	15 Underperform	$3.94M	―	-231.27%	―	―	85.78%

60 Degrees Pharmaceuticals, Inc. Corporate Events

60 Degrees Pharmaceuticals Secures $5M in Recent Offering

On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. announced a Securities Purchase Agreement with institutional investors for a follow-on offering, which included shares of common stock and various warrants. The offering, which closed on July 16, 2025, generated approximately $5 million in gross proceeds, intended for general corporate purposes and working capital. The offering was made under the company’s registration statement declared effective by the SEC. This move is expected to impact the company’s financial operations and market positioning by providing additional capital for its ongoing projects.

The most recent analyst rating on (SXTP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.